Provalis PLC - Re Directorate

RNS Number:1283M
Provalis PLC
13 June 2000


                         PROVALIS PLC
                               
       Provalis appoints Neil Kirkby as Finance Director

Provalis announces today that Neil Kirkby is to be its Finance
Director. Mr Kirkby, aged 35, will join the board of  Provalis
plc  as  an  executive director on 7th August 2000. Mr  Kirkby
will  also join the Group's executive management board,  which
includes Phil Gould (CEO of Provalis plc), Mark Keeling (MD of
Provalis   Healthcare  Ltd),  John  Curtis  (MD  of   Provalis
Diagnostics  Ltd),  Dr  Les  Davies  (R&D  Director)  and  Lee
Greenbury (Company Secretary).

Mr   Kirkby  joins  Provalis  from  Drummond  Group   PLC,   a
manufacturer  of  high quality textiles, where  he  was  Group
Finance  Director.  Prior to Drummond he held  senior  finance
positions  at  API Group PLC, a large supplier  of  print  and
packaging,  and  also  Fine  Art Development  PLC.  Mr  Kirkby
originally trained with Deloitte & Touche.

Commenting  on  the appointment, Phil Gould,  Chief  Executive
Officer  of Provalis said "I am delighted to welcome  Neil  to
the  Provalis  team. Neil's public company, corporate  finance
and  commercial and strategic development experience  will  be
important  as  Provalis moves forward and drives for  business
development  and enhanced profitability in its Healthcare  and
Medical  Diagnostic businesses, as well as seeking to maximise
its return from its Therapeutic R&D activities".


Provalis - Internet Website ; http://www.provalis.com

"Safe  Harbor"  Statement  under  the  US  Private  Securities
Litigation  Reform Act of 1995:  Some or all of the statements
in  this  document that relate to future plans,  expectations,
events,   performances  and  the  like  are  forward   looking
statements  as defined in the US Private Securities Litigation
Reform  Act  of 1995.  Actual results of events  could  differ
materially  from  those  described  in  the  forward   looking
statements  due to a variety of factors, including  those  set
forth  in  Provalis plc -s filings with the US  Securities  and
Exchange Commission.

For further information:-

Dr Phil Gould, Provalis plc,  Tel:  01244 833463
Mr Lee Greenbury, Provalis plc,  Tel:  01244 833402
Lisa Baderoon, Buchanans Communications,  Tel:  020 7466 5000

Notes to Editors

Provalis  PLC  (LSE.PRO  and  NASDAQ.PVLS)  is  an  integrated
healthcare  company with three separate divisions  focused  on
the supply and sale of prescription medicines, the development
and global sale of medical diagnostics, and the development of
new   therapeutic  products,  such  as  vaccines   to   combat
infectious diseases.

The three divisions are:-

Healthcare  -  This Division carries on the supply,  sale  and
marketing  of branded, third party, prescription medicines  in
the  UK  to  GP -s  and  Hospitals through its  own  regionally
managed  sales  force.   Its current  product  range  includes
products  for  use  in the medical areas of  gastroenterology,
osteoporosis, migraine and dermatology.

Medical Diagnostics - This Division carries on the development
and  sale  of medical diagnostic products for sale  to  global
markets  through a number of distributors.  The  Division  has
recently launched the innovative diagnostic products Glycosal(TM) 
and  Osteosal(TM),  in  the  areas of diabetes  and  osteoporosis 
respectively, and also has a world-wide franchise  in  medical 
diagnostic products for infectious diseases.

Therapeutic Research & Development - This Division carries  on
the development of new therapeutic products, including vaccine
candidates  for  infectious diseases.   A  number  of  vaccine
candidates are at the pre-clinical stage.


END
BOABRGDLGDBGGGD
Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024